| Rituximab plus prednisone (n = 38) | Prednisone alone (n = 36) | Total (N = 74) | |
| Sex | |||
| Female, n (%) | 27 (71) | 15 (42) | 42 (57) |
| Male, n (%) | 11 (29) | 21 (58) | 32 (43) |
| Age, years | |||
| Mean (SD) | 54·7 (16·2) | 51·8 (13·4) | 53·3 (14·8) |
| Median (range) | 55·0 (25–79) | 49·0 (30–79) | 51·5 (25–79) |
| Baseline weight, kg | |||
| Mean (SD) | 68·3 (21·4) | 75·2 (18·7) | 71·7 (20·3) |
| Median (range) | 63·0 (43–177) | 74·5 (43–155) | 69·5 (43–177) |
| Baseline body mass index, kg m−2 | |||
| Mean (SD) | 27·0 (15·26) | 25·7 (5·13) | 26·4 (11·45) |
| Median (range) | 25·4 (15–115) | 25·3 (17–46) | 25·3 (15–115) |
| Severity of PV (by Harman's criteria) | |||
| Moderate, n (%) | 5 (13) | 3 (8) | 8 (11) |
| Severe, n (%) | 33 (87) | 33 (92) | 66 (89) |
| PDAI score, 0–250 | |||
| Mean (SD) | 34·1 (29·5) | 46·6 (23·6) | 40·1 (27·4) |
| Median (range) | 26·0 (3–131) | 55·0 (7–106) | 33·0 (3–131) |
| Duration of cutaneous lesions, days | |||
| Mean (SD) | 111·3 (274·3) | 94·4 (134·0) | 103·1 (216·4) |
| Median (range) | 38·5 (0–1590) | 50·0 (0–622) | 44·0 (0–1590) |
| Duration of mucosal lesions, days | |||
| Mean (SD) | 138·7 (131·5) | 115·4 (130·1) | 127·4 (130·5) |
| Median (range) | 109·0 (0–571) | 84·0 (1–391) | 94·0 (0–691) |
| Rituximab plus prednisone (n = 38) | Prednisone alone (n = 36) | Total (N = 74) | |
| Sex | |||
| Female, n (%) | 27 (71) | 15 (42) | 42 (57) |
| Male, n (%) | 11 (29) | 21 (58) | 32 (43) |
| Age, years | |||
| Mean (SD) | 54·7 (16·2) | 51·8 (13·4) | 53·3 (14·8) |
| Median (range) | 55·0 (25–79) | 49·0 (30–79) | 51·5 (25–79) |
| Baseline weight, kg | |||
| Mean (SD) | 68·3 (21·4) | 75·2 (18·7) | 71·7 (20·3) |
| Median (range) | 63·0 (43–177) | 74·5 (43–155) | 69·5 (43–177) |
| Baseline body mass index, kg m−2 | |||
| Mean (SD) | 27·0 (15·26) | 25·7 (5·13) | 26·4 (11·45) |
| Median (range) | 25·4 (15–115) | 25·3 (17–46) | 25·3 (15–115) |
| Severity of PV (by Harman's criteria) | |||
| Moderate, n (%) | 5 (13) | 3 (8) | 8 (11) |
| Severe, n (%) | 33 (87) | 33 (92) | 66 (89) |
| PDAI score, 0–250 | |||
| Mean (SD) | 34·1 (29·5) | 46·6 (23·6) | 40·1 (27·4) |
| Median (range) | 26·0 (3–131) | 55·0 (7–106) | 33·0 (3–131) |
| Duration of cutaneous lesions, days | |||
| Mean (SD) | 111·3 (274·3) | 94·4 (134·0) | 103·1 (216·4) |
| Median (range) | 38·5 (0–1590) | 50·0 (0–622) | 44·0 (0–1590) |
| Duration of mucosal lesions, days | |||
| Mean (SD) | 138·7 (131·5) | 115·4 (130·1) | 127·4 (130·5) |
| Median (range) | 109·0 (0–571) | 84·0 (1–391) | 94·0 (0–691) |
PV, pemphigus vulgaris; PDAI, Pemphigus Disease Area Index.
| Rituximab plus prednisone (n = 38) | Prednisone alone (n = 36) | Total (N = 74) | |
| Sex | |||
| Female, n (%) | 27 (71) | 15 (42) | 42 (57) |
| Male, n (%) | 11 (29) | 21 (58) | 32 (43) |
| Age, years | |||
| Mean (SD) | 54·7 (16·2) | 51·8 (13·4) | 53·3 (14·8) |
| Median (range) | 55·0 (25–79) | 49·0 (30–79) | 51·5 (25–79) |
| Baseline weight, kg | |||
| Mean (SD) | 68·3 (21·4) | 75·2 (18·7) | 71·7 (20·3) |
| Median (range) | 63·0 (43–177) | 74·5 (43–155) | 69·5 (43–177) |
| Baseline body mass index, kg m−2 | |||
| Mean (SD) | 27·0 (15·26) | 25·7 (5·13) | 26·4 (11·45) |
| Median (range) | 25·4 (15–115) | 25·3 (17–46) | 25·3 (15–115) |
| Severity of PV (by Harman's criteria) | |||
| Moderate, n (%) | 5 (13) | 3 (8) | 8 (11) |
| Severe, n (%) | 33 (87) | 33 (92) | 66 (89) |
| PDAI score, 0–250 | |||
| Mean (SD) | 34·1 (29·5) | 46·6 (23·6) | 40·1 (27·4) |
| Median (range) | 26·0 (3–131) | 55·0 (7–106) | 33·0 (3–131) |
| Duration of cutaneous lesions, days | |||
| Mean (SD) | 111·3 (274·3) | 94·4 (134·0) | 103·1 (216·4) |
| Median (range) | 38·5 (0–1590) | 50·0 (0–622) | 44·0 (0–1590) |
| Duration of mucosal lesions, days | |||
| Mean (SD) | 138·7 (131·5) | 115·4 (130·1) | 127·4 (130·5) |
| Median (range) | 109·0 (0–571) | 84·0 (1–391) | 94·0 (0–691) |
| Rituximab plus prednisone (n = 38) | Prednisone alone (n = 36) | Total (N = 74) | |
| Sex | |||
| Female, n (%) | 27 (71) | 15 (42) | 42 (57) |
| Male, n (%) | 11 (29) | 21 (58) | 32 (43) |
| Age, years | |||
| Mean (SD) | 54·7 (16·2) | 51·8 (13·4) | 53·3 (14·8) |
| Median (range) | 55·0 (25–79) | 49·0 (30–79) | 51·5 (25–79) |
| Baseline weight, kg | |||
| Mean (SD) | 68·3 (21·4) | 75·2 (18·7) | 71·7 (20·3) |
| Median (range) | 63·0 (43–177) | 74·5 (43–155) | 69·5 (43–177) |
| Baseline body mass index, kg m−2 | |||
| Mean (SD) | 27·0 (15·26) | 25·7 (5·13) | 26·4 (11·45) |
| Median (range) | 25·4 (15–115) | 25·3 (17–46) | 25·3 (15–115) |
| Severity of PV (by Harman's criteria) | |||
| Moderate, n (%) | 5 (13) | 3 (8) | 8 (11) |
| Severe, n (%) | 33 (87) | 33 (92) | 66 (89) |
| PDAI score, 0–250 | |||
| Mean (SD) | 34·1 (29·5) | 46·6 (23·6) | 40·1 (27·4) |
| Median (range) | 26·0 (3–131) | 55·0 (7–106) | 33·0 (3–131) |
| Duration of cutaneous lesions, days | |||
| Mean (SD) | 111·3 (274·3) | 94·4 (134·0) | 103·1 (216·4) |
| Median (range) | 38·5 (0–1590) | 50·0 (0–622) | 44·0 (0–1590) |
| Duration of mucosal lesions, days | |||
| Mean (SD) | 138·7 (131·5) | 115·4 (130·1) | 127·4 (130·5) |
| Median (range) | 109·0 (0–571) | 84·0 (1–391) | 94·0 (0–691) |
PV, pemphigus vulgaris; PDAI, Pemphigus Disease Area Index.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
